-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Enhancing the supply chain security level of high-end biopharmaceutical products and equipment" has been written into the "14th Five-Year Plan for Bioeconomic Developmen.
Under this new policy, the industry believes that it means that the biopharmaceutical equipment industry will usher in a favorable situati.
Biomedical equipment industry (photo source: Pharmaceutical Network) On May 10, the "14th Five-Year Plan" Bioeconomic Development Plan issued by China proposed that it should conform to the new trend of "treatment-centered" to "health-centered" , to develop biomedicine oriented to people's life and health, and meet the people's new expectations for more protection of life and heal.
The plan is clear, focusing on improving the people's health protection capabilities, focusing on drugs, vaccines, advanced diagnosis and treatment technologies and equipment, biomedical materials, precision medicine, inspection and testing, and biological health care, e.
, to enhance original innovation capabilities, and strengthen drug regulatory scientific resear.
Enhance the security level of the supply chain of high-end biomedical products and equipme.
Broad prospects for biopharmaceutical equipment The biopharmaceutical industry is a strategic emerging industry in Chi.
With the intensification of aging and the escalating consumption level, China's biopharmaceutical industry is developing rapidly, and the market prospect is very bro.
According to the Frost & Sullivan Report, it is expected that by 2024, the scale of China's biopharmaceutical market will exceed US$100 billi.
In this context, the related equipment industry in the industrial chain will also usher in opportuniti.
The industry pointed out that pharmaceutical equipment is an important part of the biomedical industry cha.
In recent years, with the rapid development of China's biopharmaceutical industry, related biopharmaceutical products have been continuously approved, and the global biopharmaceutical CDMO production capacity has been gradually transferred to China, China's pharmaceutical equipment market demand continues to expand, and there is a broad space for developme.
According to CIC data, the scale of the global pharmaceutical equipment industry has exceeded 500 billion yuan at present, and it will exceed 700 billion yuan in 202 Among them, the Chinese market is currently approaching 100 billion yuan, and it is expected to reach 200 billion yuan in 202 From the perspective of industry development status, the domestic pharmaceutical equipment market, especially high-end pharmaceutical machines, has long relied on imported manufacturers, and domestic pharmaceutical machine companies have little right to spe.
.
However, in recent years, as local companies continue to increase investment in innovation and research and development, and the domestic alternatives brought about by the epidemic, the entire pharmaceutical equipment industry has gradually accelerated its transformation and upgrading from low-end to mid-to-high-e.
At present, many sub-sectors have broken the monopoly of foreign capital, but due to the low stability of key processes and few high-end enterprises, some sub-sectors such as high-end analytical instruments still need to be broken throu.
The "Planning" clearly enhances the supply chain security level of high-end biomedical equipment, which is expected to bring benefits to leading companies with strength in the biomedical equipment indust.
Some individual stocks rose slightly or affected by the good ne.
In the afternoon of May 10, some pharmaceutical equipment stocks ro.
As of 13:32 on May 10, Tofflon rose slightly by 43% to 385 yuan, with a total market value of 2898 billi.
Statistics show that Tofflon is a comprehensive pharmaceutical equipment service provider that provides pharmaceutical companies with overall solutions for pharmaceutical processes, core equipment and system engineeri.
After years of development, there are more than 10,000 sets of pharmaceutical equipment and pharmaceutical manufacturing systems serving more than 2,000 pharmaceutical companies in more than 40 countries and regions around the wor.
It is understood that in the field of biopharmaceutical equipment, Tofflon began to lay out the bioengineering track as early as 201 In 2021, the company acquired Qianchun Bio and invested in Saipu, and gradually expanded to the downstream consumables/devices fie.
Starting from 2019, its bioengineering segment income began to generate inco.
In 2019, the bioengineering single machine and system achieved income of 69451 million yuan, and then maintained a high growth trend in the next few years, with an increase of 220% and 3015% respectively from 2020 to 202 The proportions reached 27% and 263% respective.
With the increase in the business proportion of the bioengineering segment, the overall gross profit margin of Tofflon also continued to increase, and the profitability was further enhanc.
In 2021, the company's gross profit margin is 410%, an increase of 34 percentage points year-on-year; its net profit margin is 214%, an increase of 36 percentage points year-on-ye.
Among them, the gross profit margin of bioengineering stand-alone and system reached 576%
In addition to Tofflon, related pharmaceutical equipment stocks such as Chengyitong rose 28%, Canaan Technology rose 86%, and Aoxing Life Technology edged up 3
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Under this new policy, the industry believes that it means that the biopharmaceutical equipment industry will usher in a favorable situati.
Biomedical equipment industry (photo source: Pharmaceutical Network) On May 10, the "14th Five-Year Plan" Bioeconomic Development Plan issued by China proposed that it should conform to the new trend of "treatment-centered" to "health-centered" , to develop biomedicine oriented to people's life and health, and meet the people's new expectations for more protection of life and heal.
The plan is clear, focusing on improving the people's health protection capabilities, focusing on drugs, vaccines, advanced diagnosis and treatment technologies and equipment, biomedical materials, precision medicine, inspection and testing, and biological health care, e.
, to enhance original innovation capabilities, and strengthen drug regulatory scientific resear.
Enhance the security level of the supply chain of high-end biomedical products and equipme.
Broad prospects for biopharmaceutical equipment The biopharmaceutical industry is a strategic emerging industry in Chi.
With the intensification of aging and the escalating consumption level, China's biopharmaceutical industry is developing rapidly, and the market prospect is very bro.
According to the Frost & Sullivan Report, it is expected that by 2024, the scale of China's biopharmaceutical market will exceed US$100 billi.
In this context, the related equipment industry in the industrial chain will also usher in opportuniti.
The industry pointed out that pharmaceutical equipment is an important part of the biomedical industry cha.
In recent years, with the rapid development of China's biopharmaceutical industry, related biopharmaceutical products have been continuously approved, and the global biopharmaceutical CDMO production capacity has been gradually transferred to China, China's pharmaceutical equipment market demand continues to expand, and there is a broad space for developme.
According to CIC data, the scale of the global pharmaceutical equipment industry has exceeded 500 billion yuan at present, and it will exceed 700 billion yuan in 202 Among them, the Chinese market is currently approaching 100 billion yuan, and it is expected to reach 200 billion yuan in 202 From the perspective of industry development status, the domestic pharmaceutical equipment market, especially high-end pharmaceutical machines, has long relied on imported manufacturers, and domestic pharmaceutical machine companies have little right to spe.
.
However, in recent years, as local companies continue to increase investment in innovation and research and development, and the domestic alternatives brought about by the epidemic, the entire pharmaceutical equipment industry has gradually accelerated its transformation and upgrading from low-end to mid-to-high-e.
At present, many sub-sectors have broken the monopoly of foreign capital, but due to the low stability of key processes and few high-end enterprises, some sub-sectors such as high-end analytical instruments still need to be broken throu.
The "Planning" clearly enhances the supply chain security level of high-end biomedical equipment, which is expected to bring benefits to leading companies with strength in the biomedical equipment indust.
Some individual stocks rose slightly or affected by the good ne.
In the afternoon of May 10, some pharmaceutical equipment stocks ro.
As of 13:32 on May 10, Tofflon rose slightly by 43% to 385 yuan, with a total market value of 2898 billi.
Statistics show that Tofflon is a comprehensive pharmaceutical equipment service provider that provides pharmaceutical companies with overall solutions for pharmaceutical processes, core equipment and system engineeri.
After years of development, there are more than 10,000 sets of pharmaceutical equipment and pharmaceutical manufacturing systems serving more than 2,000 pharmaceutical companies in more than 40 countries and regions around the wor.
It is understood that in the field of biopharmaceutical equipment, Tofflon began to lay out the bioengineering track as early as 201 In 2021, the company acquired Qianchun Bio and invested in Saipu, and gradually expanded to the downstream consumables/devices fie.
Starting from 2019, its bioengineering segment income began to generate inco.
In 2019, the bioengineering single machine and system achieved income of 69451 million yuan, and then maintained a high growth trend in the next few years, with an increase of 220% and 3015% respectively from 2020 to 202 The proportions reached 27% and 263% respective.
With the increase in the business proportion of the bioengineering segment, the overall gross profit margin of Tofflon also continued to increase, and the profitability was further enhanc.
In 2021, the company's gross profit margin is 410%, an increase of 34 percentage points year-on-year; its net profit margin is 214%, an increase of 36 percentage points year-on-ye.
Among them, the gross profit margin of bioengineering stand-alone and system reached 576%
In addition to Tofflon, related pharmaceutical equipment stocks such as Chengyitong rose 28%, Canaan Technology rose 86%, and Aoxing Life Technology edged up 3
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
